Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 10—October 2008

Prophylaxis after Exposure to Coxiella burnetii

Claire E. MoodieComments to Author , Herbert A. Thompson, Martin I. Meltzer, and David L. Swerdlow
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

Main Article

Table 1

Input values used in the primary and secondary analyses of PEP efficacy*

Variable Primary analysis
(sensitivity analysis) Sensitivity analyses
Less virulent More virulent
Exposure (0.10, 0.25, 0.50, 1.00) NA NA NA
Efficacy of doxycycline PEP (8–12 d postexposure) 0.82 (0.82–0.965) 0.965 0.40 (22,23)
Efficacy of trimethoprim-sulfamethoxazole PEP (8–12 d postexposure) 0.82 (0.40–0.965) 0.965 0.40 (21,24,25)
Asymptomatic infection w/o PEP (all groups) 0.50 0.65 0.40 (1,3,5,7,8,26)
Full recovery after acute (gp) 0.74 Residual (0.934) Residual (0.576) (79)
Full recovery after acute illness (hr) 0.28 Residual (0.739) Residual (0.076) (79)
Full recovery after acute illness (pw) 0.08 Residual (0.57) Residual (0.02) (79)
Probability of hospitalization and recovery given acute illness (gp) 0.04 0.01 0.05 (5,7,27)
Probability of hospitalization and recovery given acute illness (hr) 0.01 0.01 0.05 (5,7)
Probability of hospitalization and recovery given acute illness (pw) 0.01 0.01 0.02 (5,7)
Q fever fatigue syndrome (gp) 0.20 0.05 0.30 (1,10,16,2830)
Q fever fatigue syndrome (hr) 0.30 0.05 0.20 (1,10,16,2830)
Q fever fatigue syndrome (pw) 0.03 Residual (0.03) Residual (0.04) (1,10,16,17,2830)
Death from acute illness (gp) 0.01 0.001 0.024 (7,911)
Death from acute illness (hr and pw) 0.02 0.001 0.024 (7,911)
Chronic disease (gp) 0.01 0.005 0.05 (8,11,12,26,31)
Chronic disease (hr) 0.39 0.20 0.65 (13,14,31)
Chronic disease (pw) 0.86 0.39 0.90 (17)
Endocarditis (all groups) 0.65 0.60 0.90 (1,7,8)
Death from endocarditis (all groups) 0.10 0.05 0.60 (1,3,7,8,11,15,32)
Death from other chronic diseases (all groups) 0.30 0.05 0.60 (9)
Abortion or neonatal death 0.38 0.25 0.56 (8,14 ,17,21)
Premature birth/low birth weight baby 0.33 0.25 0.28 (8,14,17,21)
Healthy, unaffected baby 0.29 0.50 0.16 (8,14,17,21)

*PEP, postexposure prophylaxis; NA, not applicable; gp, general population; hr, high-risk; pw, pregnant women. See online Appendix Table 1 for a detailed explanation of how the primary input values were selected.

Main Article

  1. Health Protection Agency Center for Infections. Interim guidelines for action in the event of a deliberate release: Q fever. 2005. Version 1.4, revised 2007 Jun 18 [cited 2008 Aug 1]. Available from
  2. McQuiston  JH, Childs  JE. Q fever in humans and animals in the United States. Vector Borne Zoonotic Dis. 2002;2:17991. DOIPubMedGoogle Scholar
  3. Kagawa  FT, Wehner  JH, Mohindra  V. Q fever as a biological weapon. Semin Respir Infect. 2003;18:18395.PubMedGoogle Scholar
  4. United States Army Medical Research Institute for Infectious Diseases. Medical management of biological casualities handbook. 5th ed. Frederick (MD): The Institute; 2004.
  5. Dupuis  G, Petite  J, Peter  O, Vouilloz  M. An important outbreak of human Q fever in a Swiss Alpine valley. Int J Epidemiol. 1987;16:2827. DOIPubMedGoogle Scholar
  6. Franz  DR, Jahrling  PB, Friedlander  AM, McClain  DJ, Hoover  DL, Bryne  WR, Clinical recognition and management of patients exposed to biological warfare agents. JAMA. 1997;278:399411. DOIPubMedGoogle Scholar
  7. Maurin  M, Raoult  D. Q fever. Clin Microbiol Rev. 1999;12:51853.PubMedGoogle Scholar
  8. Raoult  D, Tissot-Dupont  H, Foucault  C, Gouvernet  J, Fournier  PE, Bernit  E, Q fever 1985–1998. Clinical and epidemiologic features of 1,383 infections. Medicine (Baltimore). 2000;79:10923. DOIPubMedGoogle Scholar
  9. Bossi  P, Tegnell  A, Baka  A, van Loock  F, Werner  A, Hendriks  J, Bichat guidelines for the clinical management of Q fever and bioterrorism-related Q fever. Euro Surveill. 2004;9:E1920.PubMedGoogle Scholar
  10. Kermode  M, Yong  K, Hurley  S, Marmion  B. An economic evaluation of increased uptake in Q fever vaccination among meat and agricultural industry workers following implementation of the National Q Fever Management Program. Aust N Z J Public Health. 2003;27:3908. DOIPubMedGoogle Scholar
  11. Fournier  PE, Marrie  TJ, Raoult  D. Diagnosis of Q fever. J Clin Microbiol. 1998;36:182334.PubMedGoogle Scholar
  12. Cutler  SJ, Paiba  GA, Howells  J, Morgan  KL. Q fever—a forgotten disease? Lancet Infect Dis. 2002;2:7178. DOIPubMedGoogle Scholar
  13. Fenollar  F, Fournier  PE, Carrieri  MP, Habib  G, Messana  T, Raoult  D. Risks factors and prevention of Q fever endocarditis. Clin Infect Dis. 2001;33:3126. DOIPubMedGoogle Scholar
  14. Maltezou  HC, Raoult  D. Q fever in children. Lancet Infect Dis. 2002;2:68691. DOIPubMedGoogle Scholar
  15. Raoult  D, Houpikian  P, Tissot  DH, Riss  JM. rditi-Djiane J, Brouqui P. Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch Intern Med. 1999;159:16773. DOIPubMedGoogle Scholar
  16. Marmion  BP, Storm  PA, Ayres  JG, Semendric  L, Mathews  L, Winslow  W, Long-term persistence of Coxiella burnetii after acute primary Q fever. QJM. 2005;98:720. DOIPubMedGoogle Scholar
  17. Raoult  D, Fenollar  F, Stein  A. Q fever during pregnancy: diagnosis, treatment, and follow-up. Arch Intern Med. 2002;162:7014. DOIPubMedGoogle Scholar
  18. Centers for Disease Control and Prevention. Bioterrorism agents/diseases [cited 2006 Sep 9]. Available from
  19. Benenson  AS, Tigertt  WD. Studies on Q fever in man. Trans Assoc Am Physicians. 1956;69:98104.PubMedGoogle Scholar
  20. Byrne  WR. Chapter 26: Q fever. In: Zajtchuk R, editor. Textbook of military medicine: medical aspects of chemical and biological warfare. Washington: US Department of the Army, Surgeon General and the Borden Institute; 1997. p. 523–37.
  21. Carcopino  X, Raoult  D, Bretelle  F, Boubli  L, Stein  A. Managing Q fever during pregnancy: the benefits of long-term cotrimoxazole therapy. Clin Infect Dis. 2007;45:54855. DOIPubMedGoogle Scholar
  22. Haddix  AC, Hillis  SD, Kassler  WJ. The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women. Sex Transm Dis. 1995;22:27480. DOIPubMedGoogle Scholar
  23. Nuovo  J, Menikow  J, Paliescheskey  M, King  J, Mowers  R. Cost-effectiveness analysis of five different antibiotic regimens for the treatment of uncomplicated Chlamydia trachomatis cervicitis. J Am Board Fam Pract. 1995;8:716.PubMedGoogle Scholar
  24. Gomolin  IH, Siami  PF, Reuning-Scherer  J, Haverstock  DC, Heyd  A. Efficacy and safety of ciprofloxacin oral suspension versus trimethoprim-sulfamethoxazole oral suspension for treatment of older women with acute urinary tract infection. J Am Geriatr Soc. 2001;49:160613. DOIPubMedGoogle Scholar
  25. DiRienzo  AG, van Der  HC, Finkelstein  DM, Frame  P, Bozzette  SA, Tashima  KT. Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection. AIDS Res Hum Retroviruses. 2002;18:8994. DOIPubMedGoogle Scholar
  26. Franz  DR, Jahrling  PB, McClain  DJ, Hoover  DL, Byrne  WR, Pavlin  JA, Clinical recognition and management of patients exposed to biological warfare agents. Clin Lab Med. 2001;21:43573.PubMedGoogle Scholar
  27. Marrie  TJ. Coxiella burnetii pneumonia. Eur Respir J. 2003;21:7139. DOIPubMedGoogle Scholar
  28. Ayres  JG, Flint  N, Smith  EG, Post-infection fatigue syndrome following Q fever. QJM. 1998;91:10523. DOIPubMedGoogle Scholar
  29. Marmion  BP, Shannon  M, Maddocks  I, Storm  P, Penttila  I. Protracted debility and fatigue after acute Q fever. Lancet. 1996;347:9778. DOIPubMedGoogle Scholar
  30. Smith  DL, Ayres  JG, Blair  I, Burge  PS, Carpenter  MJ, Caul  EO, A large Q fever outbreak in the West Midlands: clinical aspects. Respir Med. 1993;87:50916. DOIPubMedGoogle Scholar
  31. Raoult  D, Levy  PY, Dupont  HT, Chicheportiche  C, Tamalet  C, Gastaut  JA, Q fever and HIV infection. AIDS. 1993;7:816. DOIPubMedGoogle Scholar
  32. Siegman-Igra  Y, Kaufman  O, Keysary  A, Rzotkiewicz  S, Shalit  I. Q fever endocarditis in Israel and a worldwide review. Scand J Infect Dis. 1997;29:419.PubMedGoogle Scholar
  33. Fowler  RA, Sanders  GD, Bravata  DM, Nouri  B, Gastwirth  JM, Peterson  D, Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax. Ann Intern Med. 2005;142:60110.PubMedGoogle Scholar
  34. Sabbaj  J, Hoagland  VL, Shih  WJ. Multiclinic comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections. Antimicrob Agents Chemother. 1985;27:297301.PubMedGoogle Scholar
  35. Talan  DA, Stamm  WE, Hooton  TM, Moran  DJ, Burke  T, Travani  A, Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA. 2000;283:158390. DOIPubMedGoogle Scholar
  36. Kocak  Z, Hatipoglu  CA, Ertem  G, Kinikli  S, Tufan  A, Irmak  H, Trimethoprim-sulfamethoxazole induced rash and fatal hematologic disorders. J Infect. 2006;52:e4952. DOIPubMedGoogle Scholar
  37. See  S, Mumford  JM. Trimethoprim/sulfamethoxazole-induced toxic epidermal necrolysis. Ann Pharmacother. 2001;35:6947. DOIPubMedGoogle Scholar
  38. Fennelly  KP, Davidow  AL, Miller  SL, Connell  N, Ellner  JJ. Airborne infection with Bacillus anthracis—from mills to mail. Emerg Infect Dis. 2004;10:9961001.PubMedGoogle Scholar

Main Article

Page created: July 13, 2010
Page updated: July 13, 2010
Page reviewed: July 13, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.